279 related articles for article (PubMed ID: 16416758)
1. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A
Pharmacoeconomics; 2005; 23 Suppl 1():3-16. PubMed ID: 16416758
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
Laux G; Heeg B; van Hout BA; Mehnert A
Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
Achilla E; McCrone P
Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
[TBL] [Abstract][Full Text] [Related]
5. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.
Chue PS; Heeg B; Buskens E; van Hout BA
Pharmacoeconomics; 2005; 23 Suppl 1():62-74. PubMed ID: 16416762
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?
Annemans L
Pharmacoeconomics; 2005; 23 Suppl 1():1-2. PubMed ID: 16416757
[No Abstract] [Full Text] [Related]
14. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia.
Chue P; Chue J
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):259-69. PubMed ID: 22812548
[TBL] [Abstract][Full Text] [Related]
15. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
Carswell C; Wheeler A; Vanderpyl J; Robinson E
Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
19. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.
Quintero J; Oyagüez I; González B; Cuervo-Arango I; García I; Casado MA
Clin Drug Investig; 2016 Jun; 36(6):479-90. PubMed ID: 27000061
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]